Dermasol® 0.05% cream: Each 10 gm cream contains Clobetasol Propionate BP 5 mg.
Dermasol® 0.05% ointment: Each 10 gm ointment contains Clobetasol Propionate BP 5 mg.
Clobetasol Propionate is a highly potent topical steroid. It has both local anti inflammatory and immunosuppressive activity. Clobetasol, as the Propionate salt, is only used topically on the skin and its effects are limited to the local anti inflammatory activity. When given systemically it has standard glucocorticoid activity and binds with high affinity to the glucocorticoid receptor. Clobetasol Propionate inhibits the adherence of neutrophils and monocyte-macrophages; to the capillary endothelial cells of inflamed area. Clobetasol blocks the effect of macrophage migration inhibitory factor and decreases the activation of plasminogen to plasmin.
Dermasol® is indicated in:
Apply sparingly to the affected area once or twice daily until improvement occurs. As with other highly active topical steroid preparations, therapy should be discontinued when control is achieved. If a longer course is necessary, it is recommended that treatment should not be continued for more than four weeks without the patient’s condition being observed. Repeated short courses of Dermasol® may be used to control exacerbations. If continuous steroid treatment is necessary, a less potent preparation should be used. In very resistant lesions, especially where there is hyperkeratosis, the anti-inflammatory effect of Dermasol® can be enhanced, if necessary, by occluding the treatment area with polythene film. Only overnight occlusion is usually adequate to bring about a satisfactory response. Thereafter, improvement can usually be maintained by application without occlusion.
CONTRAINDICATION AND PRECAUTION:
Clobetasol Propionate is contraindicated in:
Long term continuous therapy with Clobetasol Propionate should be avoided, particularly in infants and children, in whom adrenal suppression occurs readily. If Clobetasol Propionate is required for use in children, it is recommended that the treatment should be reviewed on weekly basis. It should be noted that the infants napkin may act as occlusive dressing. The face more than other area of the body, may exhibit atrophic changes after prolonged treatment with potent topical corticosteroids. This must be borne in mind when treating facial conditions which warrants use of Clobetasol Propionate and frequent observation of the patient is important.
Clobetasol Propionate should be avoided in pregnant women. Mothers using large amounts of the drug should be aware of potential excretion in milk.
Acute overdose is very unlikely to occur. However, in the case of chronic overdosage or misuse, the features of hypercorticism may appear and in this situation topical steroids should be discontinued.
Store in a cool and dry place, away from light. Keep out of reach of children.